<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03750136</url>
  </required_header>
  <id_info>
    <org_study_id>IIKNT-001/2018</org_study_id>
    <nct_id>NCT03750136</nct_id>
  </id_info>
  <brief_title>Furosemide Alone or Unexpectedly With Solution of Hypertonic Saline in Nephrotic Syndrome</brief_title>
  <acronym>FLUSH-NS</acronym>
  <official_title>HSS (Hypertonic Saline Solution) Plus High Dose Furosemide vs High Dose Furosemide in Nephrotic Syndrome - a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will test the hypothesis that hypertonic saline on top of standard diuretic&#xD;
      treatment will help achieve adequate diuresis in patients with nephrotic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Edema is one of the major clinical manifestations of nephrotic syndrome. All patients are&#xD;
      initially treated with diuretics and sodium restriction but the results are sometimes not&#xD;
      satisfactory. Hypertonic saline solutions have been studied in congestive heart failure and a&#xD;
      meta-analysis confirmed it's role in achieving adequate diuresis and protecting patients&#xD;
      against acute kidney injury although the proposed mechanism of action is not known (osmotic&#xD;
      action?, inhibition of renin-angiotensin-aldostrerone system?, increase in renal perfusion?,&#xD;
      myocardial contractility?). The investigators therefore hypothesized that it may exert&#xD;
      beneficial effects also in nephrotic syndrome.&#xD;
&#xD;
      Treatment protocol:&#xD;
&#xD;
      A prospective placebo-controlled randomized trial. Subjects will be randomized to high-dose&#xD;
      furosemide vs high-dose furosemide plus hypertonic intravenous saline in a 1:1 fashion. All&#xD;
      subjects will receive furosemide tid (starting with 3x40 mg i.v.) with or without hypertonic&#xD;
      saline solution (3x100 ml of 3% NaCl - in a combined infusion lasting 10 minutes). Subjects&#xD;
      randomized to furosemide only will receive 3x100 ml of 5% glucose (in a combined infusion&#xD;
      lasting 10 minutes). The dose of furosemide will be determined by the investigator based on&#xD;
      patients weight, severity of edema, 24-h urine volume, kidney function. In case of poor&#xD;
      clinical response (urine volume below 1000 ml) the investigator will be able to titrate the&#xD;
      furosemide dose up to 3x180 mg i.v. All patients will be kept on low-salt diet and water&#xD;
      restriction (500-1000 ml/day), their weight will assessed every morning before breakfast and&#xD;
      measurement of 24-h urine volume will be performed every day. Additionally BNP levels will be&#xD;
      measured at baseline and after 5 days of treatment. Treatment will be continued for 5 days.&#xD;
      The primary measure of efficacy will be urine volume and the rate of acute kidney injury&#xD;
      (AKI), secondary measure of efficacy will be the expected decrease in brain natriuretic&#xD;
      peptides (BNP) levels and the length of hospitalization.&#xD;
&#xD;
      Hydrochlorothiazide, spironolactone and other diuretics use will be contraindicated during&#xD;
      the study. Patients will be required to receive standard concurrent therapy as determined by&#xD;
      their attending physician and according to current guidelines (including steroids and other&#xD;
      immunosuppresives).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diuresis</measure>
    <time_frame>5 days</time_frame>
    <description>ml of diuresis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalisation</measure>
    <time_frame>14 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP levels</measure>
    <time_frame>5 days</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>high-dose furosemide &amp; hypertonic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>furosemide i.v., 3% NaCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>furosemide i.v.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>high dose furosemide with hypertonic saline 3x daily</description>
    <arm_group_label>high-dose furosemide &amp; hypertonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide Injection</intervention_name>
    <description>high dose furosemide</description>
    <arm_group_label>high-dose furosemide</arm_group_label>
    <arm_group_label>high-dose furosemide &amp; hypertonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  30 consecutive patients with nephrotic syndrome (proteinuria over 3.5 g/day, edema,&#xD;
             hypoalbuminemia, dysproteinemia) admitted to II Nephrology Department from November&#xD;
             2018 onwards within 48h of admission,&#xD;
&#xD;
          -  age above 18,&#xD;
&#xD;
          -  informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AKI (acute kidney injury) - AKIN criteria level 3,&#xD;
&#xD;
          -  CKD (chronic kidney disease) stage 4 and 5 according to KDIGO (Kidney Disease:&#xD;
             Improving Global Outcomes),&#xD;
&#xD;
          -  concomittant heart failure NYHA (New York Heart Association) class III or worse,&#xD;
&#xD;
          -  active liver disease and liver failure,&#xD;
&#xD;
          -  terminal neoplastic disease,&#xD;
&#xD;
          -  serum sodium above 145 mmol/l,&#xD;
&#xD;
          -  pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicja Rydzewska-Rosolowska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Białystok</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicja Rydzewska-Rosolowska, MD</last_name>
    <phone>+48858317885</phone>
    <email>alicja.rosolowska@umb.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>II Department of Nephrology and Hypertension</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicja Rydzewska-Rosolowska, MD</last_name>
      <phone>+48858317885</phone>
      <email>alicja.rosolowska@umb.edu.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003 Mar;145(3):459-66.</citation>
    <PMID>12660669</PMID>
  </reference>
  <reference>
    <citation>Paterna S, Parrinello G, Amato P, Dominguez L, Pinto A, Maniscalchi T, Cardinale A, Licata A, Amato V, Licata G, Di Pasquale P. Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure. Adv Ther. 1999 Sep-Oct;16(5):219-28.</citation>
    <PMID>10915397</PMID>
  </reference>
  <reference>
    <citation>Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G, Giubilato A, Licata G. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail. 2000 Sep;2(3):305-13.</citation>
    <PMID>10938493</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Bialystok</investigator_affiliation>
    <investigator_full_name>Alicja Rydzewska-Rosołowska</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>diuretics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

